Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 2
2007 3
2008 2
2010 2
2011 2
2012 2
2013 1
2014 2
2015 6
2016 2
2017 4
2018 7
2019 1
2020 4
2021 4
2022 3
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.
Romey M, Rodepeter F, Hattesohl A, Kaiser K, Teply-Szymanski J, Heitz F, Staebler A, Serra V, Grass A, Marmé F, Timms KM, Harter P, Llop-Guevara A, Kommoss S, Boekhoff J, Denkert C. Romey M, et al. Among authors: timms km. Mod Pathol. 2024 Apr;37(4):100445. doi: 10.1016/j.modpat.2024.100445. Epub 2024 Feb 8. Mod Pathol. 2024. PMID: 38341130
Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
Wehn AK, Qiu P, Lunceford J, Yarunin A, Cristescu R, Liu L, Roessler K, Bilke S, Day JR, Timms KM, Weichert W, Marton MJ. Wehn AK, et al. Among authors: timms km. Gynecol Oncol. 2024 Jan 29;184:67-73. doi: 10.1016/j.ygyno.2024.01.016. Online ahead of print. Gynecol Oncol. 2024. PMID: 38290412 Free article.
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency.
Stecklein SR, Barlow W, Pusztai L, Timms K, Kennedy R, Logan GE, Seitz R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi GN, Godwin AK, Thompson A, Hayes DF, Sharma P. Stecklein SR, et al. Among authors: timms k. JCO Precis Oncol. 2023 Sep;7:e2300197. doi: 10.1200/PO.23.00197. JCO Precis Oncol. 2023. PMID: 37972336
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Lenz L, Neff C, Solimeno C, Cogan ES, Abramson VG, Boughey JC, Falkson C, Goetz MP, Ford JM, Gradishar WJ, Jankowitz RC, Kaklamani VG, Marcom PK, Richardson AL, Storniolo AM, Tung NM, Vinayak S, Hodgson DR, Lai Z, Dearden S, Hennessy BT, Mayer EL, Mills GB, Slavin TP, Gutin A, Connolly RM, Telli ML, Stearns V, Lanchbury JS, Timms KM. Lenz L, et al. Among authors: timms km. Breast Cancer Res Treat. 2023 Nov;202(1):191-201. doi: 10.1007/s10549-023-07046-3. Epub 2023 Aug 17. Breast Cancer Res Treat. 2023. PMID: 37589839 Free PMC article.
The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing.
Jones MA, Timms KM, Hatcher S, Cogan ES, Comeaux MS, Perry M, Morris B, Swedlund B, Elks CE, Lao-Sirieix P, Dearden S, Egile C, Brown JS, Harrington EA, Hodgson D, Stern M, Slavin TP, Mancini-DiNardo D. Jones MA, et al. Among authors: timms km. Genes Chromosomes Cancer. 2023 Oct;62(10):589-596. doi: 10.1002/gcc.23150. Epub 2023 May 24. Genes Chromosomes Cancer. 2023. PMID: 37222498
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Morgan RD, Clamp AR, Barnes BM, Timms K, Schlecht H, Yarram-Smith L, Wallis Y, Valganon-Petrizan M, MacMahon S, White R, Morgan S, McKenna S, Hudson E, Tookman L, George A, Manchanda R, Sundar SS, Nicum S, Brenton JD, Kristeleit RS, Banerjee S, McNeish IA, Ledermann JA, Taylor SS, Evans DGR, Jayson GC. Morgan RD, et al. Among authors: timms k. Int J Gynecol Cancer. 2023 Aug 7;33(8):1253-1259. doi: 10.1136/ijgc-2022-004211. Int J Gynecol Cancer. 2023. PMID: 37072323
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN. Rodler E, et al. Among authors: timms km. Lancet Oncol. 2023 Feb;24(2):162-174. doi: 10.1016/S1470-2045(22)00739-2. Epub 2023 Jan 6. Lancet Oncol. 2023. PMID: 36623515 Free PMC article. Clinical Trial.
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, Wu HT, Balcioglu M, Sethi H, Scott D, Foran J, McMillan A, Ford JM, Telli ML. Gruber JJ, et al. Among authors: timms k. Nat Cancer. 2022 Oct;3(10):1181-1191. doi: 10.1038/s43018-022-00439-1. Epub 2022 Oct 17. Nat Cancer. 2022. PMID: 36253484 Free PMC article. Clinical Trial.
52 results